Investec Bank plc has filed a public dealing disclosure under Rule 8.5 of the Takeover Code relating to Advanced Medical Solutions Group plc (AMS.L).
The disclosure was submitted in Investec’s capacity as an exempt principal trader with recognised intermediary status, dealing in a client-serving role.
Investec holds a dual role in relation to the transaction, serving as both advisor and joint broker to Advanced Medical Solutions Group plc.
The dealings covered in the filing were undertaken on 2nd June 2026, with the disclosure itself dated 3rd June 2026.
According to the filing, Investec purchased 50,000 ordinary shares in Advanced Medical Solutions Group at a price of 215.25 pence per unit.
In the same session, Investec also sold 50,000 ordinary shares in the company, with those transactions executed at a price of 215.5 pence per unit.
The buy and sell volumes were equal, each totalling 50,000 ordinary shares, reflecting typical client-serving activity by a broker acting in an intermediary capacity.
No cash-settled derivative transactions, stock-settled derivative transactions, or options were reported as part of this disclosure filing.
Investec confirmed there are no indemnity arrangements, option agreements, or understandings that could constitute an inducement to deal or refrain from dealing in relevant securities.
The firm also confirmed no agreements or understandings exist relating to voting rights under any option or derivative instrument connected to Advanced Medical Solutions Group securities.
The contact listed on the disclosure is Abhishek Gawde, reachable by telephone, with the filing submitted in compliance with Takeover Panel regulatory requirements.
Rule 8 disclosures of this kind must be made to a Regulatory Information Service, ensuring transparency around dealings during offer periods under the UK Takeover Code.
